Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3379-3388

  Uddin, Shahab ^a   Ahmed, Maqbool ^a   Bavi, Prashant ^a   El Sayed, Raafat ^a   Al Sanea, Nasser ^a   Abduljabbar, Alaa ^a   Ashari, Luai H ^a   Alhomoud, Samar ^a   Al Dayel, Fouad ^a   Hussain, Azhar R ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 1B; S PHASE KINASE ASSOCIATED PROTEIN 2; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; S PHASE KINASE ASSOCIATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ADULT; AGED; ANIMAL; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NUDE MOUSE; PROTEIN PROCESSING; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZINES; S-PHASE KINASE-ASSOCIATED PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 44849083172     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6109     Document Type: Article

References (49)

1. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
2. Khamly K, Jefford M, Michael M, et al. Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opin Investig Drugs 2005;14:607-28.
3. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
4. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994;79:13-21.
5. Ovaa H, Kessler BM, Rolen U, et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci U S A 2004;101:2253-8.
6. Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science 1995;268:522-3.
7. Cusack JC, Jr., Liu R, Xia L, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006;12:6758-64.
8. McDade TP, Perugini RA, Vittimberga FJ, Jr., et al. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery 1999;126:371-7.
9. Carrano AC, Eytan E, Hershko A, et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
10. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
11. Tsvetkov LM, Yeh KH, Lee SJ, et al. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-4.
12. Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle cell and other non-Hodgkin's B-cell lymphomas. Blood 2007;110:1631-8.
13. Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002;110:633-41.
14. Hershko D, Bornstein G, Ben-Izhak O, et al. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001;91:1745-51.
15. Yang G, Ayala G, De Marzo A, et al. Thompson TC, Harper JW. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002;8:3419-26.
16. Soligo D, Servida F, Delia D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126-35.
17. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998;58:4342-8.
18. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-6.
19. Adams J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001;28:613-9.
20. Richardson PG. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003;1:596-600.
21. Bazzaro M, Lee MK, Zoso A, et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006;66:3754-63.
22. Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006;11:245-54.
23. Hussain AR, Al-Jomah NA, Siraj AK, et al. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007;67:3888-97.
24. Uddin S, Ah-Kang J, Ulaszek J, et al. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci U S A 2004;101:147-52.
25. Uddin S, Hussain AR, Al-Hussein KA, et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-8.
26. Uddin S, Hussain AR, Al-Hussein KA, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-86.
27. Bavi P, Jehan Z, Atizado V, et al. Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1708-18.
28. Shapira M, Ben-Izhak O, Bishara B, et al. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer 2004;8:1615-21.
29. Levkau B, Koyama H, Raines EW, et al. Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol Cell 1998;1:553-63.
30. Coulombe P, Rodier G, Bonneil E, et al. N-terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome. Mol Cell Biol 2004;24:6140-50.
31. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
32. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
33. Dulic V, Stein GH, Far DF, et al. Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2-M-phase transition. Mol Cell Biol 1998;18:546-57.
34. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
35. Chen F, Harrison LE. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal 2005;17:809-16.
36. Dan HC, Sun M, Kaneko S, et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004;279:5405-12.
37. Gardner RC, Assinder SJ, Christie G, et al. Characterization of peptidyl boronic acid inhibitors of mammalian 20S and 26S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J 2000;2:447-54.
38. Rivett AJ, Gardner RC. Proteasome inhibitors: from in vitro uses to clinical trials. J Pept Sci 2000;6:478-88.
39. Ganoth D, Bornstein G, Ko TK, et al. The cell-cycle regulatory protein Cks1 is required for SCF (Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001;3:321-4.
40. Chiappetta G, De Marco C, Quintiero A, et al. Overexpression of the S-phase kinase-associated protein 2 in thyroid cancer. Endocr Relat Cancer 2007;14:405-20.
41. Timmerbeul I, Garrett-Engele CM, Kossatz U, et al. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci U S A 2006;38:14009-14.
42. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005;23:4776-89.
43. Gastman BR. Apoptosis and its clinical impact. Head Neck 2001;23:409-25.
44. Nunez G, Benedict MA, Hu Y, et al. Caspases: the proteases of the apoptotic pathway. Oncogene 1998;24:3237-45.
45. Richardson P. Clinical update: proteasome inhibitors in hematologic malignancies. Cancer Treat Rev 2003;29 Suppl 1:33-9.
46. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
47. Frankel A, Man S, Elliott P, et al. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000;6:3719-28.
48. Navas TA, Nguyen AN, Hideshima T, et al. Inhibition of p38a MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X (L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006;20:1017-27.
49. An J, Rettig MB. Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther 2007;6:61-9.